# Erectile Dysfunction Drug Shows Mixed Results in Alzheimer's

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/ctad/123938) · 2026-11-17 · Medicine
Page: https://themorning.science/story/erectile-dysfunction-drug-shows-mixed-results-in-alzheimer-s-c039c0975e8370f5
Kind: research · Impact: medium

## In brief

- Mirodenafil (known as AR1001), an oral phosphodiesterase-5 inhibitor, is approved in South Korea to treat erectile dysfunction.
- In the phase III POLARIS-AD trial in people with early Alzheimer's disease, mirodenafil showed mixed results.
- The source text is truncated, so the full trial outcomes are not available here.

## Why it matters

It tests whether an existing approved drug could be repurposed for early Alzheimer's disease, but mixed phase III results mean no clear benefit has been established.

## Coverage

- [Erectile Dysfunction Drug Shows Mixed Results in Alzheimer's](https://www.medpagetoday.com/meetingcoverage/ctad/123938) — MedPageToday.com - medical news for physicians, 2026-11-17

Tags: alzheimer's, clinical trial, drug repurposing, phosphodiesterase-5 inhibitor, erectile dysfunction

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
